AH
TEVA icon

Andreas Halvorsen’s Teva Pharmaceuticals TEVA Stock Holding History

Andreas Halvorsen’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,532,119
Closed -$51.1M – 97
2025
Q3 		$51.1M Sell
2,532,119
-9,149,214
-78% -$161M 0.13% 72
2025
Q2 		$196M Buy
11,681,333
+1,555,855
+15% +$25.1M 0.57% 57
2025
Q1 		$156M Buy
10,125,478
+3,621,993
+56% +$64.7M 0.49% 59
2024
Q4 		$143M Sell
6,503,485
-1,064,048
-14% -$19.4M 0.46% 54
2024
Q3 		$136M Buy
+7,567,533
New +$132M 0.5% 53
2016
Q4 		– Sell
-19,684,219
Closed -$906M – 77
2016
Q3 		$906M Sell
19,684,219
-8,052,436
-29% -$420M 3.91% 6
2016
Q2 		$1.39B Sell
27,736,655
-5,234,967
-16% -$279M 5.92% 4
2016
Q1 		$1.76B Buy
32,971,622
+7,927,847
+32% +$465M 7.77% 3
2015
Q4 		$1.64B Buy
25,043,775
+16,171,125
+182% +$999M 6.2% 4
2015
Q3 		$501M Buy
+8,872,650
New +$575M 1.92% 16
2015
Q2 		– Sell
-228,600
Closed -$14.2M – 68
2015
Q1 		$14.2M Buy
+228,600
New +$13.3M 0.06% 55

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Andreas Halvorsen's TEVA Position: Q4 2025 in Review

Andreas Halvorsen sold out of Teva Pharmaceuticals (TEVA) in Q4 2025, closing a stake of 2,532,119 shares — an estimated $51.1M sold.

Andreas Halvorsen first reported a position in TEVA in Q1 2015 and held it in 11 quarters. The position peaked at $1.76B in Q1 2016. 631 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

  • Andreas Halvorsen reported no remaining Teva Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Andreas Halvorsen sold 2,532,119 Teva Pharmaceuticals shares in Q4 2025, an estimated $51.1M.
  • Andreas Halvorsen first reported a position in Teva Pharmaceuticals in Q1 2015 and held it in 11 quarters.
  • Andreas Halvorsen's Teva Pharmaceuticals position peaked at $1.76B in Q1 2016.
  • 631 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on Viking Global Investors's 13F filing for Q4 2025, filed 17 Feb 2026.